

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Trevor Donald Scott
Date of last notice	6 November 2013

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Beneficiary of Ordinary Shares under registered holders Essex Castle Limited and Centralo Limited.
Date of change	9 October 2014
No. of securities held prior to change	Indirect interest in 50,118,249 Ordinary Shares and direct interest in 20,000,000 unlisted options with an exercise price of A\$0.0377 per option.
Class	Ordinary Shares and unlisted options
Number acquired	20,000,000 Ordinary Shares
Number disposed	20,000,000 unlisted options
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	A\$754,000 (\$0.0377 per share)
No. of securities held after change	Indirect interest in 50,118,249 Ordinary Shares and direct interest in 20,000,000 Ordinary Shares.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of shares following exercise on 29 September 2014 of unlisted options to acquire Ordinary Shares.</p>
--	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<p>Detail of contract</p>	<p>Not applicable</p>
<p>Nature of interest</p>	<p>Not applicable</p>
<p>Name of registered holder (if issued securities)</p>	<p>Not applicable</p>
<p>Date of change</p>	<p>Not applicable</p>
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	<p>Not applicable</p>
<p>Interest acquired</p>	<p>Not applicable</p>
<p>Interest disposed</p>	<p>Not applicable</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>Not applicable</p>
<p>Interest after change</p>	<p>Not applicable</p>

Part 3 – +Closed period

<p>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</p>	<p>Not applicable</p>
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	<p>Not applicable</p>
<p>If prior written clearance was provided, on what date was this provided?</p>	<p>Not applicable</p>

+ See chapter 19 for defined terms.